184 related articles for article (PubMed ID: 38196202)
1. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
2. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
3. TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma.
Brunelli M; Gobbo S; Malpeli G; Sirgiovanni G; Caserta C; Munari E; Francesconi S; Caliò A; Martignoni G; Cimadamore A; Veccia A; Antonelli A; Tucci M; Pierconti F; Hattab IM; Eccher A; Ascani S; Milella M; Buffoni L; Cheng L; Bracarda S
Pathologica; 2024 Feb; 116(1):55-61. PubMed ID: 38482675
[TBL] [Abstract][Full Text] [Related]
4. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma.
Tekin B; Cheville JC; Herrera Hernandez L; Negron V; Smith CY; Jenkins SM; Dasari S; Enninga EAL; Norgan AP; Menon S; Cubilla AL; Whaley RD; Jimenez RE; Thompson RH; Leibovich BC; Karnes RJ; Boorjian SA; Pagliaro LC; Erickson LA; Guo R; Gupta S
Hum Pathol; 2023 Dec; 142():42-50. PubMed ID: 37977513
[TBL] [Abstract][Full Text] [Related]
5. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
6. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
Hoffman-Censits JH; Lombardo KA; Parimi V; Kamanda S; Choi W; Hahn NM; McConkey DJ; McGuire BM; Bivalacqua TJ; Kates M; Matoso A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):619-625. PubMed ID: 33901032
[TBL] [Abstract][Full Text] [Related]
7. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
Abbas M; Heitplatz B; Bernemann C; Boegemann M; Trautmann M; Schrader AJ; Wardelmann E; Schlack K
Oncol Lett; 2023 Dec; 26(6):527. PubMed ID: 38020299
[TBL] [Abstract][Full Text] [Related]
10. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
11. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
[TBL] [Abstract][Full Text] [Related]
12. Re: Assessment of PD-L1, TROP2, and NECTIN-4 Expression in Penile Squamous Cell Carcinoma.
Linxweiler J; Klümper N; Mink J; Eckstein M; Junker K
Eur Urol; 2024 Jun; 85(6):586-587. PubMed ID: 38485575
[No Abstract] [Full Text] [Related]
13. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
Vidula N; Yau C; Rugo H
Breast Cancer Res Treat; 2022 Aug; 194(3):569-575. PubMed ID: 35789445
[TBL] [Abstract][Full Text] [Related]
14. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer.
Wucherpfennig S; Rose M; Maurer A; Cassataro MA; Seillier L; Morsch R; Hammad E; Baldia PH; Ecke TH; Vögeli TA; Knüchel R; Gaisa NT
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768978
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
17. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
Aggen DH; Chu CE; Rosenberg JE
Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
[TBL] [Abstract][Full Text] [Related]
18. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract][Full Text] [Related]
19. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z
Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990
[TBL] [Abstract][Full Text] [Related]
20. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
